Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCyrille HulinSciences Po BordeauxCCCarolyne CroizierCentre Hospitalier Universitaire de Clermont-FerrandPLPascal LenainInstitut Bergonié

Discussion

Loading...

Member takes

Implication

Prospective study shows 65.8% overall response rate in 199 relapsed refractory multiple myeloma patients, suggesting teclistamab as a viable treatment option.

Key Points

  • To evaluate the effectiveness and safety of teclistamab in patients with triple-class exposed relapsed refractory multiple myeloma.
  • Prospective, multicenter, observational study
  • Involves 199 patients from 31 centers
  • Primary endpoint: overall response rate; secondary endpoints include progression-free survival and safety.
  • 65.8% overall response rate (ORR) at 6 months
  • 63% estimated progression-free survival (PFS) at 10 months
  • Cytokine release syndrome occurred in 33.2% of patients.

Cite This Study

Hulin et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d15bhttps://doi.org/10.1182/blood-2025-5836
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE2026
  2. 2REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials2026 · 1 citations
  3. 3Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience2025
  4. 4Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025
  5. 5Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies2024 · 67 citations